Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

Read more
CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

Read more
CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Read more
Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Read more
Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Read more
Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

Read more
previous arrow
next arrow
  • CD28 targeting
  • How it works

Pipeline

Hits: 24741

Bispecific antibody programs

Bispecific antibody programs

Multispecific antibody programs

Monoclonal antibody programs

Monoclonal antibody programs

Multispecific antibody programs

Back

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

Written by Mei Liang Belhumeur on . Posted in News

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

Read more

LinkedIn